AsianScientist (Jan. 3, 2012) – Amerigen Pharmaceuticals Limited and VIWA Pharmaceutical Company Limited jointly announced last week the signing of a memorandum of understanding (MOU) setting out their intention to establish a joint venture to develop and register a range of branded generic medicines for sale in China.
VIWA Pharmaceutical Company Limited is a member of the VIWA group of companies and is focused on the development, registration and commercialization of finished pharmaceutical products within China and for export to other markets.
It is anticipated that the products, once approved, would be manufactured at Amerigen’s SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party.
Separately, Amerigen and the Shanghai Fosun Omni Pharmaceutical Co. Ltd. also announced last week they had entered into a collaboration agreement regarding the development of generic oral controlled release products.
Under the terms of the agreement, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the United States and other territories. On signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialized products.
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the U.S. and China. The group’s Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province.
Source: Amerigen Pharmaceuticals.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.